Incentives for Global Public Health
Herausgeber: Pogge, Thomas; Rubenstein, Kim; Rimmer, Matthew
Incentives for Global Public Health
Herausgeber: Pogge, Thomas; Rubenstein, Kim; Rimmer, Matthew
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This book examines global health problems through the lens of public and international law, focusing on access to essential medicines.
Andere Kunden interessierten sich auch für
- Diheng XuInteractions Between Chinese Tax Incentives and WTO¿s Subsidy Rules Against the Background of EU State Aid110,99 €
- Speedy Disposition: Monetary Incentives and Policy Reform in Criminal Courts104,99 €
- Diheng XuInteractions Between Chinese Tax Incentives and WTO¿s Subsidy Rules Against the Background of EU State Aid110,99 €
- Environmental Discourses in Public and International Law183,99 €
- Michael ReismanFraudulent Evidence Before Public International Tribunals96,99 €
- Andreas KulickGlobal Public Interest in International Investment Law149,99 €
- Werner MenskiComparative Law in a Global Context117,99 €
-
-
-
This book examines global health problems through the lens of public and international law, focusing on access to essential medicines.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Cambridge University Press
- Seitenzahl: 536
- Erscheinungstermin: 24. Juni 2010
- Englisch
- Abmessung: 235mm x 157mm x 33mm
- Gewicht: 918g
- ISBN-13: 9780521116565
- ISBN-10: 0521116562
- Artikelnr.: 28915692
- Verlag: Cambridge University Press
- Seitenzahl: 536
- Erscheinungstermin: 24. Juni 2010
- Englisch
- Abmessung: 235mm x 157mm x 33mm
- Gewicht: 918g
- ISBN-13: 9780521116565
- ISBN-10: 0521116562
- Artikelnr.: 28915692
Introduction: access to essential medicines: public health and
international law Thomas Pogge, Matthew Rimmer and Kim Rubenstein; Part I.
International Trade: 1. TRIPS and essential medicines: must one size fit
all? Making the WTO responsive to the global health crisis Rochelle Cooper
Dreyfuss; 2. The TRIPS waiver as a recognition of public health concerns in
the WTO Andrew Mitchell and Tania Voon; 3. Public law challenges to the
regulation of pharmaceutical patents in the US Bilateral Free Trade
Agreements Hitoshi Nasu; 4. Global health and development: patents and
public interest Elizabeth Siew Kuan Ng; Part II. Innovation: 5. The Health
Impact Fund: boosting innovation without obstructing free access Thomas
Pogge; 6. The Health Impact Fund: a critique Kathleen Liddell; 7. A prize
system as a partial solution to the health crisis in the developing world
William W. Fisher and Talha Syed; 8. Innovation and insufficient evidence:
the case for a WTO-WHO agreement on health technology safety and
cost-effectiveness evaluation Thomas Faunce; Part III. Intellectual
Property: 9. Opening the dam: patent pools, innovation, and access to
essential medicines Dianne Nicol and Jane Nielsen; 10. Open source drug
discovery: a revolutionary paradigm or a utopian model? Krishna Ravi
Srinivas; 11. Accessing and benefit sharing avian influenza viruses through
the World Health Organization: a CBD and TRIPS compromise thanks to
Indonesia's sovereignty claim? Charles Lawson and Barbara Hocking; 12. The
Lazarus effect: the (RED) campaign and creative capitalism Matthew Rimmer;
Part IV. Health-Care: 13. Beyond TRIPS: the role of non-state actors and
access to essential medicines Noah Benjamin Novogrodsky; 14. Securing
health through rights Katharine Young; 15. The role of national laws in
reconciling constitutional right to health with TRIPS obligations: an
examination of the Glivec patent case in India Rajshree Chandra; 16.
Tipping point: Thai compulsory licenses redefine essential medicines debate
Jonathan Burton-MacLeod.
international law Thomas Pogge, Matthew Rimmer and Kim Rubenstein; Part I.
International Trade: 1. TRIPS and essential medicines: must one size fit
all? Making the WTO responsive to the global health crisis Rochelle Cooper
Dreyfuss; 2. The TRIPS waiver as a recognition of public health concerns in
the WTO Andrew Mitchell and Tania Voon; 3. Public law challenges to the
regulation of pharmaceutical patents in the US Bilateral Free Trade
Agreements Hitoshi Nasu; 4. Global health and development: patents and
public interest Elizabeth Siew Kuan Ng; Part II. Innovation: 5. The Health
Impact Fund: boosting innovation without obstructing free access Thomas
Pogge; 6. The Health Impact Fund: a critique Kathleen Liddell; 7. A prize
system as a partial solution to the health crisis in the developing world
William W. Fisher and Talha Syed; 8. Innovation and insufficient evidence:
the case for a WTO-WHO agreement on health technology safety and
cost-effectiveness evaluation Thomas Faunce; Part III. Intellectual
Property: 9. Opening the dam: patent pools, innovation, and access to
essential medicines Dianne Nicol and Jane Nielsen; 10. Open source drug
discovery: a revolutionary paradigm or a utopian model? Krishna Ravi
Srinivas; 11. Accessing and benefit sharing avian influenza viruses through
the World Health Organization: a CBD and TRIPS compromise thanks to
Indonesia's sovereignty claim? Charles Lawson and Barbara Hocking; 12. The
Lazarus effect: the (RED) campaign and creative capitalism Matthew Rimmer;
Part IV. Health-Care: 13. Beyond TRIPS: the role of non-state actors and
access to essential medicines Noah Benjamin Novogrodsky; 14. Securing
health through rights Katharine Young; 15. The role of national laws in
reconciling constitutional right to health with TRIPS obligations: an
examination of the Glivec patent case in India Rajshree Chandra; 16.
Tipping point: Thai compulsory licenses redefine essential medicines debate
Jonathan Burton-MacLeod.
Introduction: access to essential medicines: public health and
international law Thomas Pogge, Matthew Rimmer and Kim Rubenstein; Part I.
International Trade: 1. TRIPS and essential medicines: must one size fit
all? Making the WTO responsive to the global health crisis Rochelle Cooper
Dreyfuss; 2. The TRIPS waiver as a recognition of public health concerns in
the WTO Andrew Mitchell and Tania Voon; 3. Public law challenges to the
regulation of pharmaceutical patents in the US Bilateral Free Trade
Agreements Hitoshi Nasu; 4. Global health and development: patents and
public interest Elizabeth Siew Kuan Ng; Part II. Innovation: 5. The Health
Impact Fund: boosting innovation without obstructing free access Thomas
Pogge; 6. The Health Impact Fund: a critique Kathleen Liddell; 7. A prize
system as a partial solution to the health crisis in the developing world
William W. Fisher and Talha Syed; 8. Innovation and insufficient evidence:
the case for a WTO-WHO agreement on health technology safety and
cost-effectiveness evaluation Thomas Faunce; Part III. Intellectual
Property: 9. Opening the dam: patent pools, innovation, and access to
essential medicines Dianne Nicol and Jane Nielsen; 10. Open source drug
discovery: a revolutionary paradigm or a utopian model? Krishna Ravi
Srinivas; 11. Accessing and benefit sharing avian influenza viruses through
the World Health Organization: a CBD and TRIPS compromise thanks to
Indonesia's sovereignty claim? Charles Lawson and Barbara Hocking; 12. The
Lazarus effect: the (RED) campaign and creative capitalism Matthew Rimmer;
Part IV. Health-Care: 13. Beyond TRIPS: the role of non-state actors and
access to essential medicines Noah Benjamin Novogrodsky; 14. Securing
health through rights Katharine Young; 15. The role of national laws in
reconciling constitutional right to health with TRIPS obligations: an
examination of the Glivec patent case in India Rajshree Chandra; 16.
Tipping point: Thai compulsory licenses redefine essential medicines debate
Jonathan Burton-MacLeod.
international law Thomas Pogge, Matthew Rimmer and Kim Rubenstein; Part I.
International Trade: 1. TRIPS and essential medicines: must one size fit
all? Making the WTO responsive to the global health crisis Rochelle Cooper
Dreyfuss; 2. The TRIPS waiver as a recognition of public health concerns in
the WTO Andrew Mitchell and Tania Voon; 3. Public law challenges to the
regulation of pharmaceutical patents in the US Bilateral Free Trade
Agreements Hitoshi Nasu; 4. Global health and development: patents and
public interest Elizabeth Siew Kuan Ng; Part II. Innovation: 5. The Health
Impact Fund: boosting innovation without obstructing free access Thomas
Pogge; 6. The Health Impact Fund: a critique Kathleen Liddell; 7. A prize
system as a partial solution to the health crisis in the developing world
William W. Fisher and Talha Syed; 8. Innovation and insufficient evidence:
the case for a WTO-WHO agreement on health technology safety and
cost-effectiveness evaluation Thomas Faunce; Part III. Intellectual
Property: 9. Opening the dam: patent pools, innovation, and access to
essential medicines Dianne Nicol and Jane Nielsen; 10. Open source drug
discovery: a revolutionary paradigm or a utopian model? Krishna Ravi
Srinivas; 11. Accessing and benefit sharing avian influenza viruses through
the World Health Organization: a CBD and TRIPS compromise thanks to
Indonesia's sovereignty claim? Charles Lawson and Barbara Hocking; 12. The
Lazarus effect: the (RED) campaign and creative capitalism Matthew Rimmer;
Part IV. Health-Care: 13. Beyond TRIPS: the role of non-state actors and
access to essential medicines Noah Benjamin Novogrodsky; 14. Securing
health through rights Katharine Young; 15. The role of national laws in
reconciling constitutional right to health with TRIPS obligations: an
examination of the Glivec patent case in India Rajshree Chandra; 16.
Tipping point: Thai compulsory licenses redefine essential medicines debate
Jonathan Burton-MacLeod.